Chapter 4

Figures converted from Indonesian rupiah at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Cash Conversion

Across the full FY2020–FY2025 cycle, CPIN turned essentially all of its reported profit into cash: cumulative operating cash flow of $1.41bn against $1.42bn of owners' profit, a conversion ratio of 0.99. But the timing is counter-cyclical — the heavy-investment years burned free cash while the profit trough threw it off — and the record FY2025 profit is flattered only modestly (about 6% of pre-tax) by a non-cash mark on biological assets. The dividend flexes with cash, not the earnings line.

Source: derived from reported financials, FY2020–FY2025 audited statements [1]; biological assets [2].

The record profit is backed by cash

CPIN's FY2025 profit of $339M was matched, not manufactured: operating cash flow was $346M [3] [4], a 1.02 conversion of profit to cash in the record year. The direct-method statement shows why there is no receivables game behind the print: cash received from customers was $4.24bn against net sales of $4.24bn, so collections kept pace with the top line [5].

The steadier way to read cash quality in a cyclical business is across the whole cycle, and there the picture is clean: from FY2020 to FY2025, cumulative operating cash flow of $1.41bn covered 99% of the $1.42bn of profit attributable to owners. Over six years, reported earnings and cash are the same number.

Source: derived from reported financials, FY2020–FY2025 audited statements; FY2025 cash flow [6].

The chart also shows the catch, and it is a timing catch, not a quality one. In FY2021 and FY2022 operating cash flow ran well below profit — 0.59 and 0.57 of net income — because a growing business builds inventory and biological assets faster than it collects on them. In FY2023, the profit trough, the relationship inverted: cash flow of $205M ran to 1.36 of a depressed $151M profit as that working capital drained back out. Cash conversion is real, but it arrives on a different schedule than the income statement, and it is strongest exactly when reported profit is weakest.

Free cash flow disappears in the build years

The counter-cyclical timing is sharper once capital spending is netted off. CPIN spent $193M and $164M on fixed assets in FY2021 and FY2022 — against operating cash flow of $149M and $109M — so free cash flow was negative in both years, roughly −$44M and −$56M. The company funded that gap by drawing short-term bank debt, which is why the balance sheet's borrowings rose into the down-cycle rather than in the boom. As the cycle turned, capex fell to a $47M trough in FY2024 and free cash flow swung to $220M, then $244M in FY2025 even as spending more than doubled back to $102M [7].

Source: free cash flow derived from reported financials (OCF less capex), FY2020–FY2025; FY2025 cash flow [8]; dividends [9] [10].

The re-acceleration of capex is worth flagging as a watch item rather than a verdict: FY2025 fixed-asset spending of $102M, plus land and breeding-facility purchases disclosed through the year, signals CPIN is adding capacity into a downstream that its own record year showed is priced by an externally-managed supply balance (Downstream Cycle). Capacity added at the top of a spread cycle earns its return only if demand — the government's Free Nutritious Meals programme prominent among the sources — grows into it.

Biological assets: the one number the auditor singles out

The accounting-quality question a skeptic raises first about a poultry integrator is the fair-value mark on live birds. CPIN carries biological assets — growing broilers, breeding flock and hatching eggs — at fair value less costs to sell, and the balance was $315M at end-FY2025, or 11.4% of total assets [11]. It is the sole key audit matter in the FY2025 audit, flagged by the group's auditor (a member firm of Ernst & Young) as material and dependent on significant management estimates — day-old-chick selling prices, productivity, mortality and cultivation costs for the breeding flock [12]. A year earlier the same line was $292M, which the auditor likewise put at 11% of consolidated assets [13].

The mark flows through the income statement on its own line, and it is pro-cyclical: a gain of $28M in FY2025 and $18M in FY2024, but a loss of $4M in FY2023 [14] [15]. The swing helps in a good year and hurts in a bad one, on top of the operating spread it sits beside.

Source: consolidated statements of profit or loss, FY2023–FY2025 [16] [17].

The reassuring part is the size. The FY2025 fair-value gain of $28M is 6.1% of pre-tax profit of $463M — a real contribution to the record, but a minority one, and it is verified by the auditor against near-year-end sales invoices for the growing flock rather than modelled in the abstract [18]. This is not an earnings engine dressed up as a fair-value mark.

The genuine exposure is broader than the mark itself. Biological assets of $315M plus inventories of $684M are $1.00bn, or 36% of total assets, and both are valued on prices — chicken and feed — that move with the same cycle that drives the operating spread [19]. A downturn that compresses the live-bird spread would also press the carrying value of these two lines, so the same event shows up twice: once in the operating result and once in the fair-value and net-realisable-value adjustments. That is a feature of the accounting, honestly disclosed, not a manipulation — but it means reported profit amplifies the cycle in both directions.

The dividend follows the cash, not the profit line

CPIN's payout history is the clearest evidence that management runs the business off cash and balance-sheet capacity rather than the reported-earnings line. For FY2022 — a year of $190M reported profit but negative free cash flow and rising debt — the company paid no dividend at all, retaining the entire year's profit [20]. For FY2023 — the profit trough, but a year of recovered cash flow — it did the opposite, paying out roughly 92% of a depressed $151M profit: a Rp100 interim in November 2023 and a Rp30 final, Rp130 per share and $139M in total [21].

The recovery years then normalised the payout back toward half of earnings — Rp108 per share ($110M) on FY2024 and Rp180 per share ($177M, a 52.3% payout) on the record FY2025, the latter approved at the May 2026 annual meeting [22] [23].

Source: FY2022 nil dividend [24]; FY2023 and FY2025 dividends [25] [26]; cash dividends paid [27].

For an income-oriented reader, the implication is direct: this is a variable dividend, not a progressive one. The payout was zero as recently as FY2022 and could be again if a down-cycle coincides with a capex build. What the record does support is that the policy is disciplined rather than stretched — CPIN cut when cash was tight and paid generously when cash recovered, and the balance sheet that carried it through the FY2021–22 build (a conservative funding mix established in Business and Cycle) is why the dividend could be a shock absorber rather than a constraint. The FY2025 dividend of $177M was covered 1.4 times by free cash flow of $244M; the question for the next trough is whether capex plans leave that cushion intact.

Cash conversion confirms that the record earnings are real money, which raises rather than settles the through-line: the level of that cash is still set by the downstream spread, and the same cycle that lifts profit, free cash flow and the fair-value mark together would pull all three back down at once.